Cargando…
Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
Autores principales: | Rapoport, Aaron P, Stadtmauer, Edward A, Vogl, Dan T, Weiss, Brendan, Binder-Scholl, Gwendolyn K, Smethurst, Dominic P, Finklestein, Jeffrey, Kulikovskaya, Irina, Gupta, Minnal, Brewer, Joanna E, Bennett, Alan D, Gerry, Andrew B, Pumphrey, Nick J, Tayton-Martin, Helen K, Ribeiro, Lilliam, Badros, Ashraf Z, Yanovich, Saul, Akpek, Gorgun, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Bruce, Levine L, Jakobsen, Bent K, June, Carl H, Kalos, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990335/ http://dx.doi.org/10.1186/2051-1426-1-S1-P30 |
Ejemplares similares
-
NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015) -
Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012) -
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
por: McCormack, Emmet, et al.
Publicado: (2012) -
Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies
por: Bhatnagar, Bhavana, et al.
Publicado: (2013) -
Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)